TP53 gene mutations occur in 5–10% of all MDS and AML cases [2], including 20–25% of the low-risk MDS with isolated del 5q, where they are often monoallelic [3] and 40–50% of MDS and AML with complex karyotypes, where they are generally biallelic [4]. Here, TP53 is linked to acute myeloid leukemia.